Project Details
Description
A Randomized, Double-blind, Placebo-controlled, Paralles, 26-Week, Phase 3 study of 2 Doses of an Alpha-7Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or
Status | Finished |
---|---|
Effective start/end date | 10/1/13 → 9/30/15 |
Funding
- ENVIVO PHARMACEUTICALS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.